Capstan Therapeutics, Inc. has launched immediately with $165 million in financing to mix cell remedy and genetic medicines to assist convey safer, first-in-class medicines to extra sufferers in a number of indications.
Capstan Therapeutics’ foundational precision in vivo engineering know-how builds on analysis performed within the laboratories of mRNA and cell remedy scientists on the College of Pennsylvania.
Capstan Therapeutics’ funding features a not too long ago closed $102 million collection A financing led by Pfizer Ventures and joined by Leaps by Bayer, Eli Lilly and Firm, Bristol Myers Squibb, Polaris Companions, Alexandria Enterprise Investments, and all current buyers, which follows a $63 million seed financing led by Novartis Enterprise Fund and OrbiMed and joined by RA Capital, and Vida Ventures in November 2021.
Capstan Therapeutics plans to advance breakthrough therapies
Capstan Therapeutics plans to make use of the funds to additional its mission of advancing the scientific promise of cell-based therapies by enabling exact in vivo engineering of cells with payloads obligatory to learn sufferers throughout a number of illness classes.
Capstan Therapeutics’ modular platform contains proprietary focused lipid nanoparticles (tLNP) know-how, a set of concentrating on moieties to mediate cell type-specific uptake, and disease-specific mRNA payloads geared toward immediately engineering, or ablating pathogenic cells by way of in vivo generated CAR T cells.
Capstan Therapeutics is prioritizing packages primarily based on the potential to rework scientific requirements of care. The corporate’s preliminary efforts will deal with creating first-in-class in vivo CAR therapies, with the purpose to ship remedies in an outpatient setting, for sufferers who’ve illnesses for which there aren’t any efficient remedies.
Capstan Therapeutics additionally plans to leverage its precision supply and engineering know-how to advance new therapies for sure monogenic blood problems.
Capstan Therapeutics additionally introduced that Laura Shawver has joined the corporate as president and chief govt officer.
The corporate’s scientific founders embrace a number of from the College of Pennsylvania who authored two research establishing preclinical proof-of-concept for non-viral, in vivo CAR-T remedy that Capstan Therapeutics plans to develop and advance towards the clinic.
New remedy choices
A 2019 Nature publication demonstrated the preclinical use of ex vivo CAR-T cell remedy towards FAP, a fibrosis-related goal. A follow-on examine printed in Science earlier this yr constructed on these earlier outcomes and demonstrated the manufacturing of purposeful CAR-T cells in vivo in a mouse mannequin following a single IV administration of an mRNA encoding an anti-FAP CAR packaged in CD5-targeted-LNPs.
“Analysis performed at Penn demonstrates the large promise of harnessing mRNA and focused LNP supply to coach a affected person’s physique to make CAR-T cells in vivo, doubtlessly creating new remedy choices,” mentioned Jonathan Epstein, chief scientific officer at Penn’s Perelman College of Drugs.
“We imagine this strategy has the potential to make an necessary impression not solely in oncology, but in addition in fibrosis and plenty of different illnesses. My fellow scientific co-founders and I all look ahead to actively partnering with Capstan in our collaborative effort to develop medicines which will profit sufferers all over the world.”